Ocugen Q3 net loss narrows 82% to $3.6 million

By Public Technologies
  • Ocugen’s third-quarter 2026 net loss narrowed 82% year over year to $3.6 million.
  • Revenue rose 11% year over year to $1.95 million.
  • Cash, cash equivalents, restricted cash and short-term investments totaled $84.6 million at September 30, 2026, with expected runway into 2028.
  • OCU400 received provisional approval in The Bahamas, while an exclusive license agreement expanded its reach into the Middle East and North Africa.
  • Phase 3 OCU400 topline data are expected in the first quarter of 2027, followed by a planned Biologics License Application submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869756) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk